Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
← catalyst calendarSponsored by Xencor, Inc. (industry) · XNCR — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60actual
Sites
12
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-14 | actual | When the study began enrolling |
| Primary completion | 2025-05-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-20 | actual | The whole study's end, after follow-up |
| First posted | 2022-10-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Head and Neck Squamous Cell Carcinoma
- Melanoma Excluding Uveal Melanoma
- Non-small Cell Lung Cancer, Squamous or Non-squamous
- Urothelial Carcinoma
- Renal Cell Carcinoma, Clear Cell
- Castration-resistant Prostate Cancer
- Ovarian Cancer, Epithelial
- TNBC - Triple-Negative Breast Cancer
- Colorectal Cancer
Interventions
- Biological: XmAb®808
- Biological: Keytruda® (pembrolizumab)
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (TEAEs)
measured Up to 5 years
Incidence of dose-limiting toxicities (DLTs)
measured 49 days
Permalink · XNCR's whole pipeline · Catalyst calendar · Every registered study · What changed